# Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of DA-2803 in Healthy Subjects

> **NCT04906109** · PHASE1 · COMPLETED · sponsor: **Dong-A ST Co., Ltd.** · enrollment: 96 (actual)

## Conditions studied

- Hepatitis B

## Interventions

- **DRUG:** Vemlidy Tab
- **DRUG:** DA-2803 Tab

## Key facts

- **NCT ID:** NCT04906109
- **Lead sponsor:** Dong-A ST Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-12
- **Primary completion:** 2021-10-05
- **Final completion:** 2021-10-05
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2022-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04906109

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04906109, "Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of DA-2803 in Healthy Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04906109. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*